Aegerion Pharmaceuticals Announces Fourth-Quarter and Year-End 2012 Financial Results
06. März 2013 07:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative,...
Aegerion Pharmaceuticals Observes Rare Disease Day
28. Februar 2013 08:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 28, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces Key Business and Financial Objectives for 2013 as the Company Prepares for U.S. Launch of JUXTAPID(TM) (lomitapide) Capsules
07. Januar 2013 07:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 7, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative,...
FDA Approves Aegerion Pharmaceuticals' JUXTAPID(TM) (lomitapide) Capsules for Homozygous Familial Hypercholesterolemia (HoFH)
24. Dezember 2012 07:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 24, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering...
Aegerion Pharmaceuticals Announces Participation at Wells Fargo Securities 2012 Healthcare Conference
13. Juni 2012 08:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 13, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces Participation at Jefferies 2012 Global Healthcare Conference
30. Mai 2012 08:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 30, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces Oral Presentation of Phase III Lomitapide Data at European Atherosclerosis Society Conference
29. Mai 2012 08:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 29, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces First Quarter 2012 Financial Results
01. Mai 2012 07:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 1, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces FDA Acceptance of New Drug Application for Review
30. April 2012 08:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 30, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces EMA Acceptance for Review of Marketing Authorization Application for Lomitapide
20. März 2012 07:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 20, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...